deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02207439

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Head and Neck Squamous Cell Carcinoma
Interventions Chemoradiation Nelfinavir (Viracept®) 1250 mg
Updated 15 times since 2017 Last updated: Jun 30, 2023 Started: Jul 31, 2014 Primary completion: May 31, 2021 Completion: May 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma and is currently completed. Abramson Cancer Center at Penn Medicine leads this study, which shows 15 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Apr 2023 · 19 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  4. Jul 2023 — Aug 2023 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Apr 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Sep 2021 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  3. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. May 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations